Moderna is a US biotechnology company. Its COVID-19 vaccine was approved for use in the UK on 8 January, 2021 - the third vaccine to get this approval. Moderna is expanding its production capability in Europe and UK supplies are expected in spring 2021. Moderna's share price rose after it announced encouraging early results from vaccine trials in November 2020, so news of an approved vaccine could see the share price rise further. The company uses a molecule called "messenger RNA" (or mRNA), which exists in the cells in your body, to produce medicines. We've compiled what you need to know about how to buy Moderna shares.
Since the stock market crash in March caused by coronavirus, Moderna's share price has had significant positive movement.
Its last market close was $73.94, which is 75.34% up on its pre-crash value of $18.23 and 312.84% up on the lowest point reached during the March crash when the shares fell as low as $17.91.
If you had bought $1,000 worth of Moderna shares at the start of February 2020, those shares would have been worth $1,303.79 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $3,628.24.
|52-week range||$17.91 - $178.5|
|50-day moving average||$133.0452|
|200-day moving average||$88.5551|
|Wall St. target price||$144.38|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.348|
|1 week (2021-01-15)||2.57%|
|1 month (2020-12-22)||5.64%|
|3 months (2020-10-22)||87.72%|
|6 months (2020-07-22)||59.78%|
|1 year (2020-01-22)||505.28%|
|2 years (2019-01-22)||754.63%|
|Revenue TTM||$246.7 million|
|Gross profit TTM||$-436,100,000|
|Return on assets TTM||-12.37%|
|Return on equity TTM||-29.81%|
|Market capitalisation||$49.5 billion|
TTM: trailing 12 months
There are currently 23.4 million Moderna shares held short by investors – that's known as Moderna's "short interest". This figure is 8.6% down from 25.6 million last month.
There are a few different ways that this level of interest in shorting Moderna shares can be evaluated.
Moderna's "short interest ratio" (SIR) is the quantity of Moderna shares currently shorted divided by the average quantity of Moderna shares traded daily (recently around 36.0 million). Moderna's SIR currently stands at 0.65. In other words for every 100,000 Moderna shares traded daily on the market, roughly 650 shares are currently held short.
However Moderna's short interest can also be evaluated against the total number of Moderna shares, or, against the total number of tradable Moderna shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Moderna's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Moderna shares in existence, roughly 60 shares are currently held short) or 0.0769% of the tradable shares (for every 100,000 tradable Moderna shares, roughly 77 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Moderna.
Find out more about how you can short Moderna stock.
We're not expecting Moderna to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
Over the last 12 months, Moderna's shares have ranged in value from as little as $17.91 up to $178.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Moderna's is 1.7165. This would suggest that Moderna's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca, Merck & Co., Vertex Pharmaceuticals, Biomedical Advanced Research and Development Authority, Defense Advanced Research Projects Agency, and Bill & Melinda Gates Foundation; and a research collaboration with Harvard University. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of mRNA-1273, a COVID-19 vaccine; and Catalent for fill-finish manufacturing of its COVID-19 vaccine candidate. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.